HLS Therapeutics (TSE:HLS - Free Report) had its target price hoisted by Raymond James from C$4.00 to C$5.00 in a research report report published on Friday,BayStreet.CA reports.
Separately, Stifel Nicolaus reduced their target price on shares of HLS Therapeutics from C$3.75 to C$3.25 in a report on Tuesday, August 13th.
Get Our Latest Research Report on HLS Therapeutics
HLS Therapeutics Trading Up 3.3 %
HLS traded up C$0.11 during mid-day trading on Friday, hitting C$3.42. 19,271 shares of the stock were exchanged, compared to its average volume of 27,044. The company has a market cap of C$108.72 million, a PE ratio of -3.39 and a beta of 1.07. The company has a current ratio of 2.02, a quick ratio of 1.01 and a debt-to-equity ratio of 100.44. The firm's fifty day moving average is C$3.54 and its two-hundred day moving average is C$3.50. HLS Therapeutics has a 1-year low of C$3.00 and a 1-year high of C$5.48.
About HLS Therapeutics
(
Get Free Report)
HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.
Featured Stories
Before you consider HLS Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HLS Therapeutics wasn't on the list.
While HLS Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
